Modulatory efficacy of bone metabolism and safety of denosumab versus zoledronic acid in the treatment of bone and joint osteoporosis in elderly men
Denosumab demonstrated superior efficacy in reducing fracture risk at the lumbar spine, while ZA showed greater protective effects at the hip. Although both agents significantly improved bone metabolic parameters, denosumab exhibited a more favorable safety profile in clinical application.
Authors
- Yuanjie Mao (ORCID: https://orcid.org/0000-0002-4196-7133)
- Xiaofeng Dai (ORCID: https://orcid.org/0000-0002-0006-4042)
- Jing He (ORCID: https://orcid.org/0000-0003-3904-8928)
- Zhu Haitao
- Shui Wang (ORCID: https://orcid.org/0000-0003-4268-5768)
- Weiyi Gong (ORCID: https://orcid.org/0000-0003-3152-6075)
- Peng Xiang
Institutions
- Shanghai Jiao Tong University (CN)
- Nantong University (CN)
- Yancheng Second People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-10-23
- DOI
- https://doi.org/10.3389/fphar.2025.1666421
- Primary Topic
- Bone health and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00